Mottiwala Aziz's Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 20, 2025
- Accession no.
- 0001819790-25-000059
- Filed
- Mar 20, 2025
- Trade date
- Mar 18-20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $505.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mottiwala AzizCIK 0001788542 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | Common Stock | SSaleDisposed | −3,643 | $46.29 | −$168,634.47 | 71,979 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −3,557 | $47.40 | −$168,601.8 | 68,422 | Direct | |
| Mar 20, 2025 | Common Stock | SSaleDisposed | −3,365 | $50.11 | −$168,620.15 | 65,057 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.